NAV

Pancrelipase protease

Identification

Summary

Pancrelipase proteaseis a lipase used to treat pancreatic exocrine insufficiency.

Brand Names
Cotazym, Creon, Pancrease MT, Pancreaze, Pertzye, Viokace, Zenpep
Generic Name
Pancrelipase protease
DrugBank Accession Number
DB11066
Background

Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands.2The pancrelipase protease is a mix of enzymes, formed by trypsin and chymotrypsin, that proteolytically cleave peptide bonds and are involved in food digestion.1,4The pancrelipase mixture, including pancrelipase protease, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.3

Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
其他protein based therapies
Protein Chemical Formula
Not Available
蛋白质断言age Weight
Not Available
Sequences
>sp|P00761|TRYP_PIG Trypsin OS=Sus scrofa OX=9823 PE=1 SV=1 FPTDDDDKIVGGYTCAANSIPYQVSLNSGSHFCGGSLINSQWVVSAAHCYKSRIQVRLGE HNIDVLEGNEQFINAAKIITHPNFNGNTLDNDIMLIKLSSPATLNSRVATVSLPRSCAAA GTECLISGWGNTKSSGSSYPSLLQCLKAPVLSDSSCKSSYPGQITGNMICVGFLEGGKDS CQGDSGGPVVCNGQLQGIVSWGYGCAQKNKPGVYTKVCNYVNWIQQTIAAN
>AEC11098.1 chymotrypsin C [Sus scrofa] MLGITVLAALLAYASSCGVPSFPPNLSARVVGGENAVPHSWPWQISLQYLSGDTWKHTCG GTLITSTHVLTAAHCISNSRTYRVALGKNNLEVEDEEGSLVVGVDSIFVHEKWNSLLIRN DIALIKLAEPVELSDTIQVLCLPEEGSLLPQDYPCYVTGWGRLWTNGPIAAELQQGLQPV VDHATCSQRDWWGSTVRDTMVCAGGDGVISACNGDSGGPLNCQAENGSWEVRGIVSFGSG LGCNTYKKPTVFTRVSAYIDWIDQKIQL
Download FASTA Format
Synonyms
  • Protease, pancreatic

Pharmacology

Indication

Please refer toPancrelipase.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.
了解更多
Avoid life-threatening adverse drug events & improve clinical decision support.
了解更多
Pharmacodynamics

Please refer toPancrelipase.

Mechanism of action

Pancrelipase protease acts on the peptide bonds within the proteins. The two constituents of the pancrelipase protease, trypsin, and chymotrypsin, are grouped under the family of serine proteases. Trypsin acts on lysine and arginine residues while chymotrypsin acts in hydrophobic residues such as tryptophan, tyrosine and phenylalanine. Both constituents present a catalytic site in the S1 binding pocket formed by a triad of serine, histidine and aspartate.5

Target Actions Organism
ADietary protein
cleavage
 Humans
Absorption

Please refer toPancrelipase.

Volume of distribution

Please refer toPancrelipase.

Protein binding

Please refer toPancrelipase.

Metabolism

Please refer toPancrelipase.

Route of elimination

Please refer toPancrelipase.

Half-life

Please refer toPancrelipase.

Clearance

Please refer toPancrelipase.

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
了解更多
Improve decision support & research outcomes with our structured adverse effects data.
了解更多
Toxicity

Please refer toPancrelipase.

Pathways
Not Available
Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
  • Take with food.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Images
Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image
Cotazym Pancrelipase protease(35000 units)+Pancrelipase amylase(40000 units)+Pancrelipase lipase(10000 units) Capsule Oral Organon Canada Inc. 1973-12-31 Not applicable Canada flag
Cotazym Ecs 20 Pancrelipase protease(100000 units)+Pancrelipase amylase(100000 units)+Pancrelipase lipase(25000 units) Capsule, delayed release Oral Organon Canada Inc. 1989-12-31 Not applicable Canada flag
Cotazym Ecs 4 Pancrelipase protease(11000 unit)+Pancrelipase amylase(11000 unit)+Pancrelipase lipase(4000 unit) Capsule Oral Merck Ltd. 1997-08-18 2012-01-23 Canada flag
Cotazym Ecs 8 Pancrelipase protease(45000 units)+Pancrelipase amylase(42000 units)+Pancrelipase lipase(10800 units) Capsule, delayed release Oral Organon Canada Inc. 1980-12-31 Not applicable Canada flag
Creon Pancrelipase protease(38000 [USP'U]/1)+Pancrelipase amylase(60000 [USP'U]/1)+Pancrelipase lipase(12000 [USP'U]/1) Capsule, delayed release pellets Oral Atlantic Biologicals Corps. 2010-08-13 Not applicable US flag
Creon Pancrelipase protease(9500 [USP'U]/1)+Pancrelipase amylase(15000 [USP'U]/1)+Pancrelipase lipase(3000 [USP'U]/1) Capsule, delayed release Oral AbbVie Inc. 2009-04-30 Not applicable US flag
Creon Pancrelipase protease(19000 [USP'U]/1)+Pancrelipase amylase(30000 [USP'U]/1)+Pancrelipase lipase(6000 [USP'U]/1) Capsule, delayed release pellets Oral AbbVie Inc. 2009-04-30 Not applicable US flag
Creon Pancrelipase protease(76000 [USP'U]/1)+Pancrelipase amylase(120000 [USP'U]/1)+Pancrelipase lipase(24000 [USP'U]/1) Capsule, delayed release pellets Oral Atlantic Biologicals Corps. 2010-08-13 Not applicable US flag
Creon Pancrelipase protease(19000 [USP'U]/1)+Pancrelipase amylase(30000 [USP'U]/1)+Pancrelipase lipase(6000 [USP'U]/1) Capsule, delayed release pellets Oral Atlantic Biologicals Corps. 2010-08-13 Not applicable US flag
Creon Pancrelipase protease(76000 [USP'U]/1)+Pancrelipase amylase(120000 [USP'U]/1)+Pancrelipase lipase(24000 [USP'U]/1) Capsule, delayed release pellets Oral AbbVie Inc. 2009-04-30 Not applicable US flag
Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image
Creon 10 Minimicrospheres Pancrelipase protease(37500 [USP'U]/1)+Pancrelipase amylase(33200 [USP'U]/1)+Pancrelipase lipase(10000 [USP'U]/1) Capsule, delayed release Oral Physicians Total Care, Inc. 2006-09-12 2009-09-30 US flag
Creon 20 Minimicrospheres Pancrelipase protease(75000 [USP'U]/1)+Pancrelipase amylase(66400 [USP'U]/1)+Pancrelipase lipase(20000 [USP'U]/1) Capsule, delayed release Oral Physicians Total Care, Inc. 1995-01-17 2009-09-30 US flag
Pancrelipase Pancrelipase protease(44000 [USP'U]/1)+Pancrelipase amylase(56000 [USP'U]/1)+Pancrelipase lipase(20000 [USP'U]/1) Capsule, delayed release Oral Kaiser Foundations Hospitals 2010-02-01 2010-12-31 US flag

Categories

Drug Categories
Chemical TaxonomyProvided byClassyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
3560D81V50
CAS number
9001-94-9

References

General References
  1. Schauperl M, Fuchs JE, Waldner BJ, Huber RG, Kramer C, Liedl KR: Characterizing Protease Specificity: How Many Substrates Do We Need? PLoS One. 2015 Nov 11;10(11):e0142658. doi: 10.1371/journal.pone.0142658. eCollection 2015. [Article]
  2. Creon monograph [Link]
  3. FDA approval [Link]
  4. VIVO pathophysiology [Link]
  5. EMBL-EBI [Link]
RxNav
1427034
FDA label
Download (483 KB)

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
4 Active Not Recruiting Treatment Cystic Fibrosis (CF)/Pancreatitis, Chronic 1
4 Completed Not Available Human Immunodeficiency Virus (HIV) Infections/蛋白尿 1
4 Completed 其他 Coinfection, HIV/Hepatitis C Virus (HCV) Infection 1
4 Completed Treatment Cystic Fibrosis (CF) 1
4 Completed Treatment Cystic Fibrosis (CF)/Exocrine Pancreatic Insufficiency 2
4 Completed Treatment HIV Lipodystrophy Syndrome 1
4 Completed Treatment Human Immunodeficiency Virus (HIV) Infections 1
4 Completed Treatment Human Immunodeficiency Virus Type 1 (HIV-1) 1
4 Completed Treatment Human Immunodeficiency Virus Type 1 (HIV-1) Infection 1
4 Completed Treatment Pancreatic Insufficiency 1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Form Route Strength
Capsule, delayed release pellets Oral
Capsule, delayed release Oral
Capsule, delayed release pellets Not applicable
Capsule, delayed release pellets
Granule, delayed release Oral
Capsule Oral
Tablet, coated Oral
Capsule, coated pellets Oral
Capsule, extended release Oral
Capsule, coated Oral 22500 U Ph.Eu
Tablet Oral
Powder Oral
Prices
Not Available
Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region
US9198871 No 2015-12-01 2030-02-07 US flag
US8562979 No 2013-10-22 2028-02-20 US flag
US8562980 No 2013-10-22 2028-02-20 US flag
US8562981 No 2013-10-22 2028-02-20 US flag
US8221747 No 2012-07-17 2028-02-20 US flag
US8562978 No 2013-10-22 2028-02-20 US flag
US8246950 No 2012-08-21 2028-02-20 US flag
US7658918 No 2010-02-09 2028-02-20 US flag

Properties

State
Solid
Experimental Properties
Property Value Source
water solubility 1 mg/ml Monograph

Drug created at December 03, 2015 16:51 / Updated at May 21, 2021 10:21